宝山监狱服刑人员的心理健康状况及其相关因素分析

目的 了解监狱内服刑人员的心理状况及其相关因素.方法 采用自编一般情况调查表、焦虑自评量表(SAS)、抑郁自评量表(SDS)、症状自评量表(SCL-90)、对宝山监狱2000例服刑人员进行评定.结果 服刑人员的焦虑、抑郁总分显著高于正常人群(P＜0.001);而SAS总分高于正常人群上限者占39.9%,SDS总分高于正常人群上限者占52.6%;既有焦虑又有抑郁情绪的人占35.4%;负性情绪中未婚和离婚者显著高于已婚者(P＜0.05);焦虑、抑郁情绪与学历、刑期、是否愿意与心理工作者交流、症状自评量表总分均有不同程度的相关性.其中焦虑情绪在不同刑期之间经F检验有显著差异(P＜0.05),SCL-90总分、均分、8项因子分显著高于常模(P＜0.001),其总分的高低与年龄、学历、SAS总分、SDS总分显著相关,而不同刑期的服刑人员之间的量表总分经F检验则无显著差异(P＞0.05).结论 服刑人员中较多的人存在着心理障碍.     

脑梗死患者的生活质量与其焦虑、抑郁情绪的相关性研究

目的 探讨脑梗死患者的生活质量与其焦虑、抑郁情绪的关系。方法 采用Zung焦虑自评量表（SAS）、Zung抑郁自评量表（SDS）及生活质量综合评定问卷（GQOLI）对80例脑梗死患者（脑梗死组）及80名健康人（对照组）进行问卷调查，并对生活质量与其焦虑、抑郁情绪作相关分析。结果 脑梗死患者的生活质量总分及躯体功能、心理功能、社会功能3个维度评分均明显低于对照组（P〈0．01），而SAS及SDS评分均明显高于对照组（P〈0．01）。脑梗死患者的生活质量总分及躯体功能、心理功能、社会功能3个维度评分均与SAS及SDS评分呈显著性负相关。结论 脑梗死患者的生活质量较差，焦虑、抑郁情绪明显；其生活质量与焦虑、抑郁情绪密切相关。     

焦虑、抑郁情绪对癫(癎)患者生活质量的影响

目的 探讨焦虑、抑郁情绪对癫(癎)患者生活质量的关系.方法 应用生活质量综合评定问卷(GQOLI)、Zung焦虑自评量表 (SAS)及Zung抑郁自评量表 (SDS)对60例癫(癎)患者(癫(癎)组)及60名健康自愿者(对照组)进行评定,并对生活质量与焦虑、抑郁作相关分析.结果 癫(癎)患者的生活质量总分及躯体功能、心理功能、社会功能、物质生活4个维度分均明显低于对照组(P＜0.01),而SAS及SDS评分则均明显高于对照组(P＜0.01);生活质量总分及躯体功能、心理功能、社会功能、物质生活4个维度分均与SAS及SDS评分呈显著性负相关.结论 癫(癎)患者的生活质量较差,焦虑、抑郁情绪明显;其生活质量与焦虑、抑郁情绪密切相关.     

焦虑、抑郁情绪对癫患者生活质量的影响

目的 探讨焦虑、抑郁情绪对癫(癎)患者生活质量的关系.方法 应用生活质量综合评定问卷(GQOLI)、Zung焦虑自评量表 (SAS)及Zung抑郁自评量表 (SDS)对60例癫(癎)患者(癫(癎)组)及60名健康自愿者(对照组)进行评定,并对生活质量与焦虑、抑郁作相关分析.结果 癫(癎)患者的生活质量总分及躯体功能、心理功能、社会功能、物质生活4个维度分均明显低于对照组(P＜0.01),而SAS及SDS评分则均明显高于对照组(P＜0.01);生活质量总分及躯体功能、心理功能、社会功能、物质生活4个维度分均与SAS及SDS评分呈显著性负相关.结论 癫(癎)患者的生活质量较差,焦虑、抑郁情绪明显;其生活质量与焦虑、抑郁情绪密切相关.     

2型糖尿病患者负性情绪研究

目的：探讨负性情绪与2型糖尿病的关系。方法：对51例2型糖尿病患者与50例正常对照者进行负性情绪比较，采用生活事件量表（LES）、社会支持评定量表（SSRS）、症状自评量表（SCL-90）、抑郁自评量表（SDS）及焦虑自评量表（SAS）测评。结果：与对照组比较，糖尿病组的负性生活事件刺激量和总刺激量得分均显著较高（P均〈0．01）；而社会支持总分、主观支持分及支持利用度分均显著较低（P均〈0．01）。糖尿病组SCL-90总分及躯体化、人际关系敏感、抑郁、焦虑、敌对、恐惧6个因子分与SDS、SAS评分均显著高于对照组（P〈0．05或P〈0．01）。结论：2型糖尿病患者存在明显的负性情绪，有针对性的心理干预可能对其防治起重要作用。     

焦虑、抑郁情绪对癫患者生活质量的影响

目的探讨焦虑、抑郁情绪对癫患者生活质量的关系。方法应用生活质量综合评定问卷(GQOLI)、Zung焦虑自评量表(SAS)及Zung抑郁自评量表(SDS)对60例癫患者(癫组)及60名健康自愿者(对照组)进行评定,并对生活质量与焦虑、抑郁作相关分析。结果癫患者的生活质量总分及躯体功能、心理功能、社会功能、物质生活4个维度分均明显低于对照组(P<0.01),而SAS及SDS评分则均明显高于对照组(P<0.01);生活质量总分及躯体功能、心理功能、社会功能、物质生活4个维度分均与SAS及SDS评分呈显著性负相关。结论癫患者的生活质量较差,焦虑、抑郁情绪明显;其生活质量与焦虑、抑郁情绪密切相关。     

脑型Wilson病患者认知功能障碍与负性情绪研究

目的 分析脑型WD患者的认知功能损害与负性情绪的特点.方法 对30例脑型WD患者和30例对照者组采用简易智能量表(MMSE)、MoCA量表进行认知功能评估.采用抑郁自评量表(SDS)和焦虑自评量表(SAS)进行情绪状态评估,并进行分析.结果 脑型WD患者组MMSE、MoCA量表评分均较正常组低,差异具有统计学意义(P<0.05);脑型WD患者组SDS评分和SAS评分均较正常组高,差异有统计学意义(P<0.01).结论 脑型WD患者存在认知功能损害和明显的抑郁和焦虑情绪.神经精神量表是客观的评价脑型WD患者神经心理状况的有效手段.     

失眠症相关因素的调查

目的探讨失眠症病人的人格特性、负性情绪等相关因素.方法采用自制失眠一般情况调查(其中包括影响睡眠相关因素调查表)、匹兹堡睡眠质量指数量表(PSQI)、EPQ、焦虑自评量表(SAS)、抑郁自评量表(SDS)对106例门诊失眠症病人进行调查,与90例健康对照组进行比较.结果①失眠组的E分低于正常组,N分、L分高于正常组(P＜0.01);②失眠组SAS、SDS评分高于正常对照组;③E分与N、SAS、SDS评分呈负相关,N分与SAS、SDS评分呈正相关,P分与SAS、SDS评分呈正相关,SAS与SDS评分呈正相关(P＜0.01);④对影响睡眠质量相关因素进行多元逐步回归分析得出焦虑、病程、经济状况、轮班制进入回归方程.结论失眠患者的人格具有内倾性和不稳定性,其负性情绪与人格特征有关,失眠可受病程、经济状况、轮班制、负性情绪的影响.     

海洛因依赖者述情障碍研究

目的:了解海洛因依赖者(PHD)述情障碍特征及与负性情绪的关系. 方法:对194例男性PHD(PHD组),采用自编一般情况问卷、多伦多述情障碍量表(TAS)、抑郁自评量表(SDS)及焦虑自评量表(SAS)进行心理评估;107名健康男性作为对照,采用TAS进行述情障碍测评. 结果:PHD组TAS总分及各因子分、SDS及SAS评分均显著高于对照组(P<0.05或P<0.01);TAS总分及因子Ⅰ、因子Ⅱ、因子Ⅳ与SDS、SAS总分均呈显著正相关(r=0.178～0.294,P均<0.05或P<0.01);TAS因子Ⅲ与SAS总分均呈显著负相关(r=-0.147,P<0.05). 结论:男性PHD存在明显述情障碍,并与负性情绪密切相关.     

护理干预对脑梗死患者负性情绪认知功能及肢体运动功能的影响

目的分析综合护理干预对脑梗死患者负性情、认知功能及肢体运动功能的影响。方法 136例脑梗死患者按照随机数字表分为2组,每组68例,对照组给予常规护理,干预组给予综合护理干预。2组患者入组时与综合干预4周、8周时采用Zung编制的抑郁自评量表(self-rating depression scale,SDS)及焦虑自评量表(self-rating anxiety scale,SAS)评定患者的抑郁、焦虑负性情绪,简易智能精神状态检查量表(mini-mental state examination,MMSE)评定认知功能,简易Fugl-Meyer运动功能评价量表(Fugl-Meyer assessment,FMA)评定肢体运动功能水平,并进行对比分析。结果入组时2组患者SDS、SAS、MMSE、FMA评分比较差异无统计学意义(P0.05);干预后4周、8周2组SDS、SAS评分均较干预前降低,MMSE、FMA评分均显著升高,差异有统计学意义(P0.05);干预后2组同期比较,干预组SDS、SAS评分均显著低于对照组,MMSE、FMA评分显著高于对照组,差异均有统计学意义(P0.05)。结论综合护理干预能显著减轻脑梗死患者的负性情绪,增强认知与肢体运动功能,有效改善患者的预后,提高患者的生命质量。     

Hepatic Considerations in the Use of Antiepileptic Drugs

Summary: Virtually all of the major antiepileptic drugs (AEDs) can cause hepatotoxicity, although fatal hepatic reactions are rare. The mechanisms, incidences, and risk profiles for such reactions differ from drug to drug. With carbamazepine and phenytoin, hepatotoxicity may be due to drug hypersensitivity. Although the profiles of patients at risk have not been well-defined for these two antiepileptic drugs, it would appear from reports in the literature that older adolescents and adults are at higher risk than children of developing serious or fatal hepatotoxicity. Once hepatotoxicity develops, mortality rates are 10–38% with phenytoin and 25% for carbamazepine. The risk profile for valproate fatal hepatotoxicity has been more clearly defined. Those at primary risk of fatal hepatic dysfunction are children under the age of 2 years who are receiving multiple anticonvulsants and also have significant medical problems in addition to severe epilepsy. The risk is considerably lower for patients over the age of 2 years on valproate monotherapy. In contrast to the risk profile with other AEDs, adults receiving valproate as monotherapy have the lowest risk of hepatotoxicity. Fatal hepatic dysfunction coincident with valproate may be the result of aberrant drug metabolism. Concomitant use of AEDs that induce microsomal P450 enzymes (e.g., phenytoin and phenobarbital) may enhance the production of a toxic metabolite, and hence the greater risk of hepatotoxicity with polypharmacy.     

Vascular Malformations and Epilepsy: Clinical Considerations and Basic Mechanisms

Summary: Vascular malformations (VMs) are associated with epilepsy. The natural history of the various VMs, clinical presentation, and tendency to provoke epilepsy determine treatment strategies. Investigations have probed the mechanisms of epileptogenesis associated with these lesions. Electrophysiologic changes are associated with epileptogenic cortex adjacent to VMs. Putative pathophysiologic mechanisms of epileptogenesis include neuronal cell loss, glial proliferation and abnormal glial physiology, altered neurotransmitter levels, free radical formation, and aberrant second messenger physiology.     

Diagnostic Difficulties and Treatment Implications

Summary: Differentiation between types of epileptic seizures has been aided in recent years by the introduction of intensive neurodiagnostic techniques and the development of increasingly detailed classification systems. Paradoxically, these developments have not simplified the task of matching the appropriate antiepileptic drug to a particular seizure type. It is reasonable to assume that anticonvulsant drugs will have different effects on different types of seizures, but faulty, circular reasoning can enter the picture if one also assumes that responses of seizures to different drugs signify different seizure types. There are several examples of differential diagnoses that can fall prey to this problem, including the diagnosis between partial seizures with secondary generalization and generalized tonic-clonic seizures, and the diagnosis between complex partial seizures and absence seizures with automatisms, among others. Considerations of etiology in future classification systems can further complicate the problem: should one then choose an anticonvulsant drug on the basis of individual seizure type or on the basis of the type of epilepsy? Ramifications of this issue extend even to the drug approval process. Official sanction is not given for use of a drug for a seizure type not included in the original efficacy studies, even if later scientific evidence shows that seizure type to be related to a type that is included. New trials must be undertaken. These problems arise from how we choose to classify seizures.     

Cognitive Dysfunction Associated with Antiepileptic Drug Therapy

Summary: Epilepsy is frequently associated with cognitive dysfunction. However, the reasons for this correlation are unclear. Possible influential factors include patient age; duration, frequency, etiology, and type of seizures; hereditary factors; psychosocial issues; and antiepileptic drug (AED) therapy. Whereas many of these factors are beyond the physician's control, AED therapy is one element that can be addressed in treatment decisions by recognizing the potential cognitive effects of particular AEDs. For example, phenobarbital impairs memory and concentration; phenytoin affects attention, problem solving ability, and performance of visuomotor tasks. In contrast, carbamazepine may affect concentration, while valproate would appear to have minimal effects on cognition. Moreover, cognitive effects of AEDs are amplified with coadministration of multiple anticonvulsants (polytherapy). A review of studies on the cognitive effects of monotherapy with AEDs, as opposed to those of polytherapy, provides evidence that drug-related cognitive dysfunction can be reversed if patients are switched to a simpler therapeutic regimen. Future research should be directed toward developing reliable measures for assessing and monitoring cognition, and understanding the particular cognitive side effects of each AED. Physicians also need to revise their opinions about which side effects are "tolerable" for epileptic patients.     

Carbamazepine Efficacy and Utilization in Children

Summary: Carbamazepine is effective for preventing partial and generalized tonic-clonic seizures in children. Although absence epilepsies are more common in children than adults, an estimated 80% of children with epilepsy have seizure types or epilepsies that are potentially responsive to carbamazepine. The differential diagnosis of ictal staring is an especially important issue in children because absence and atypical absence seizures are more prevalent in children than adults. Age-related pharmacokinetic differences and drug interactions are major considerations in children. On average, children have higher clearance rates of carbamazepine, shorter half-lives, and higher ratios of carbamazepine-10, 11-epoxide to carbamazepine than adults. In addition, children with severe epilepsy are more likely to require multiple-drug therapy, which can lead to complex drug interactions. When carbamazepine is administered along with valproate, drug protein binding interactions can cause intermittent side effects.     

Carbamazepine Efficacy in Adults With Partial and Generalized Tonic-Clonic Seizures

Summary: Carbamazepine and phenytoin are drugs of choice in initial monotherapy for adult partial and secondarily generalized tonic-clonic seizures. These designations reflect the results of the Veterans Administration Epilepsy Cooperative Study Group of 1985. An earlier comparative study of carbamazepine and phenytoin by Ramsay and associates found both drugs equally effective in controlling new-onset seizures. Among the advantages of carbamazepine is that it causes relatively few cognitive and dysmorphic side effects. Its disadvantages are its unavailability in parenteral formulation and its metabolic autoinduction. The latter must be compensated for by planned dosage increases to maintain therapeutic plasma steady-state levels during the first 2 or 3 months of treatment. Carbamazepine is judged a drug of choice in the treatment of these secondarily generalized tonic-clonic seizures, and the drug of choice in children, adolescents, and women susceptible to the dysmorphic side effects associated with other anticonvulsant agents.     

Etiologic and Preventive Aspects of Epilepsy in the Child–Bridging the Gap Between Laboratory and Clinic

Summary: Four broad categories of basic phenomena are pertinent to developing ways to prevent epilepsy. These include mechanisms of epileptogenesis, ictal initiation and temporary entrainment by the seizure discharge of normally functioning brain, seizure propagation, and control mechanisms that function both to restrain the cascade of epileptic events culminating in a seizure and to arrest the epileptic event and restore the interictal state. In newborns and children, hypoxia-ischemia is a major factor leading to epileptogenesis, and several schemes are proposed to classify, quantify, and prevent hypoxic-ischemic encephalopathy. Control mechanisms must be better understood in order to develop prophylactic recommendations for epilepsy, and an experimental model of "kindling antagonism" may increase our understanding of these. Programs of prevention of seizures in children will evolve only if basic researchers and clinicians work productively together to develop an adequate understanding of factors important in epileptogenesis and antiepileptogenic control mechanisms.     

Classification of methods in transcranial Electrical Stimulation (tES) and evolving strategy from historical approaches to contemporary innovations

Transcranial Electrical Stimulation (tES) encompasses all methods of non-invasive current application to the brain used in research and clinical practice. We present the first comprehensive and technical review, explaining the evolution of tES in both terminology and dosage over the past 100 years of research to present day. Current transcranial Pulsed Current Stimulation (tPCS) approaches such as Cranial Electrotherapy Stimulation (CES) descended from Electrosleep (ES) through Cranial Electro-stimulation Therapy (CET), Transcerebral Electrotherapy (TCET), and NeuroElectric Therapy (NET) while others like Transcutaneous Cranial Electrical Stimulation (TCES) descended from Electroanesthesia (EA) through Limoge, and Interferential Stimulation. Prior to a contemporary resurgence in interest, variations of transcranial Direct Current Stimulation were explored intermittently, including Polarizing current, Galvanic Vestibular Stimulation (GVS), and Transcranial Micropolarization. The development of these approaches alongside Electroconvulsive Therapy (ECT) and pharmacological developments are considered. Both the roots and unique features of contemporary approaches such as transcranial Alternating Current Stimulation (tACS) and transcranial Random Noise Stimulation (tRNS) are discussed. Trends and incremental developments in electrode montage and waveform spanning decades are presented leading to the present day. Commercial devices, seminal conferences, and regulatory decisions are noted. We conclude with six rules on how increasing medical and technological sophistication may now be leveraged for broader success and adoption of tES.     

Predisposing and Causative Factors in Childhood Epilepsy

Summary: We review information from large studies of defined populations, examining the role of known factors and especially of prenatal and perinatal factors in contributing to nonfebrile seizure disorders of early childhood. We depend especially, but not exclusively, on the recently completed analyses from the Collaborative Perinatal Project of the National Institute of Neurological and Communicative Disorders and Stroke, the NCPP. About 4% of children in the NCPP who had at least one non-febrile nonsymptomatic seizure by the age of 7 years had a previous seizure during acute neurologic illness, such as meningitis or during the acute illness after trauma. Many such seizures should potentially be preventable. Of children with seizures, 10% had had a neonatal seizure and 13% had had a febrile seizure. Among the hundreds of prenatal and perinatal factors explored as predictors of childhood seizure disorders, the principal predictors identified were congenital malformations of the fetus, cerebral and noncerebral; family history of certain neurologic disorders; and neonatal seizures. In agreement with the British National Child Development Study, labor and delivery factors in the NCPP appeared to contribute very little to childhood seizure disorders. Maldevelopment, rather than damage at birth to an initially intact nervous system, appeared to be the more common mechanism. Most seizure disorders of early childhood remained unexplained by the large set of prenatal and perinatal characteristics examined.     

Treatment Considerations in Anticonvulsant Monotherapy

Summary: The long-standing practice of polypharmacy in treating epilepsy is giving way to use of monotherapy. Monotherapy can improve seizure control as well as reduce the risk of serious idiosyncratic reactions, dose-related side effects, and complex drug interactions. Monotherapy also offers improved compliance and cost-effectiveness. The basis of monotherapy is accurate diagnosis and assessment of the patient's seizure type(s), followed by selection of a single appropriate anticonvulsant drug. Many patients currently treated with multiple anticonvulsants can be successfully converted to monotherapy with a carefully monitored program in which troublesome and redundant drugs are gradually withdrawn from the therapeutic regimen.